BriefsAstraZeneca licenses SAS software
On March 1, SAS announced a global licensing agreement with AstraZeneca for software to help AstraZeneca meet its strategic goals. AstraZeneca currently uses SAS software in 24 countries, primarily for clinical research and development. The new license will allow AstraZeneca to use the software for drug portfolio management – the identification of compounds that are most likely to become marketable drugs. AstraZeneca also plans to use SAS software for strategic performance management and sales and marketing.
Copyright © 2002 KDnuggets. Subscribe to KDnuggets News!